Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
We have previously shown functional differences in fibrinogen from hyperhomocysteinemic rabbits compared to that in control rabbits. This acquired dysfibrinogenemia is characterized by fibrin clots that are composed of abnormally thin, tightly packed fibers with increased resistance to fibrinolysis. Homocysteine thiolactone is a metabolite of homocysteine (Hcys) that can react with primary amines. Recent evidence suggests that Hcys thiolactone-lysine adducts form in vivo. We now demonstrate that the reaction of Hcys thiolactone with purified fibrinogen in vitro produces fibrinogen (Hcys fibrinogen) with functional properties that are strikingly similar to those we have observed in homocysteinemic rabbits. Fibrinogen purified from homocysteinemic rabbits and Hcys fibrinogen are similar in that (1) they both form clots composed of thinner, more tightly packed fibers than their respective control rabbit and human fibrinogens; (2) the clot structure could be made to be more like the control fibrinogens by increased calcium; and (3) they both form clots that are more resistant to fibrinolysis than those formed by the control fibrinogens. Further characterization of human fibrinogens showed that Hcys fibrin had similar plasminogen binding to that of the control and an increased capacity for binding tPA. However, tPA activation of plasminogen on Hcys fibrin was slower than that of the control. Mass spectrometric analysis of Hcys fibrinogen revealed twelve lysines that were homocysteinylated. Several of these are close to tPA and plasminogen binding sites. Lysines are major binding sites for fibrinolytic enzymes and are also sites of plasmin cleavage. Thus, modification of lysines in fibrinogen could plausibly lead to impaired fibrinolysis. We hypothesize that the modification of lysine by Hcys thiolactone might occur in vivo, lead to abnormal resistance of clots to lysis, and thereby contribute to the prothrombotic state associated with homocysteinemia.
Sauls
Derrick L
DL
Research Service, Durham Veteran's Affairs Medical Center, 508 Fulton Street, Durham, North Carolina 27705, USA.
Lockhart
Evelyn
E
Warren
Maria Esteban
ME
Lenkowski
Angela
A
Wilhelm
Susan E
SE
Hoffman
Maureane
M
D000595:Amino Acid Sequence; D001777:Blood Coagulation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005337:Fibrin / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism*; D005342:Fibrinolysis / Q000187:drug effects*; D006710:Homocysteine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D020138:Hyperhomocysteinemia / Q000378:metabolism*; D008239:Lysine / Q000378:metabolism; D008954:Models, Biological; D008969:Molecular Sequence Data; D010958:Plasminogen / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D011837:Radiation-Protective Agents / Q000378:metabolism / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013927:Thrombosis / Q000378:metabolism*; D010959:Tissue Plasminogen Activator / Q000494:pharmacology
D011837:Radiation-Protective Agents; D006710:Homocysteine; D005337:Fibrin; D005340:Fibrinogen; D010958:Plasminogen; C007957:homocysteine thiolactone; D010959:Tissue Plasminogen Activator; D008239:Lysine